ARVN
Arvinas, Inc.
Price Chart
Latest Quote
$7.58
+0.49 (+6.91%)
Current Price
| Previous Close | $7.09 |
| Open | $7.09 |
| Day High | $7.78 |
| Day Low | $7.08 |
| Volume | 858,387 |
Stock Information
| Shares Outstanding | 64.52M |
| Total Debt | $8.40M |
| Cash Equivalents | $614.90M |
| Revenue | $89.40M |
| Net Income | $-221.30M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $489.07M |
| EPS (TTM) | $-3.18 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-117.43M |
| Sales | $89.40M |
| Income | $-221.30M |
| Book/sh | $6.00 |
| Cash/sh | $9.53 |
| Employees | 246 |
Financial Ratios
| Quick Ratio | 5.36 |
| Current Ratio | 5.44 |
| Debt/Eq | 2.17 |
Returns & Margins
| ROA | -18.92% |
| ROE | -42.28% |
| Gross Margin | 134.45% |
| Operating Margin | -405.13% |
| Profit Margin | -247.54% |
Ownership
| Insider Ownership | 7.76% |
| Institutional Ownership | 83.28% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.20 |
| P/S | 5.47 |
| P/B | 1.26 |
Analyst Data
| Recommendation | buy |
| Target Price | $14.80 |
Technical Indicators
| SMA20 | $8.24 |
| SMA50 | $9.60 |
| SMA200 | $10.67 |
| RSI | 26.33 |
| ATR | 0.4000 |
| Shares Float | 55.95M |
| Short Float | 8.52% |
| Short Ratio | 4.85 |
| Volatility | 1.75 |
| Rel Volume | 1.04 |
Performance History
| Week | +2.16% |
| Month | -23.20% |
| Quarter | -37.77% |
| 6 Months | -41.60% |
| YTD | -33.91% |
| Year | -1.17% |
| 3 Years | -68.43% |
| 5 Years | -89.84% |
| 10 Years | -52.77% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $7.58 | 858,400 |
| 2026-06-11 | $7.09 | 817,400 |
| 2026-06-10 | $6.98 | 680,200 |
| 2026-06-09 | $7.21 | 981,300 |
| 2026-06-08 | $7.15 | 692,600 |
| 2026-06-05 | $7.42 | 649,800 |
| 2026-06-04 | $7.74 | 574,900 |
| 2026-06-03 | $7.70 | 1,271,200 |
| 2026-06-02 | $8.00 | 845,100 |
| 2026-06-01 | $8.58 | 794,200 |
| 2026-05-29 | $8.98 | 795,900 |
| 2026-05-28 | $8.84 | 509,500 |
| 2026-05-27 | $8.85 | 583,200 |
| 2026-05-26 | $8.92 | 636,200 |
| 2026-05-22 | $9.09 | 778,400 |
| 2026-05-21 | $9.10 | 782,300 |
| 2026-05-20 | $9.10 | 839,500 |
| 2026-05-19 | $8.55 | 1,480,200 |
| 2026-05-18 | $8.78 | 975,300 |
| 2026-05-15 | $9.08 | 968,100 |
| 2026-05-14 | $9.42 | 1,059,900 |
| 2026-05-13 | $9.87 | 802,200 |
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
đ° Latest News
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
Zacks âĸ 2026-06-12T12:25:00Z
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
MarketBeat âĸ 2026-06-05T16:10:37Z
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
Simply Wall St. âĸ 2026-05-16T13:40:17Z
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Benzinga âĸ 2026-05-15T20:31:07Z
Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Simply Wall St. âĸ 2026-05-14T12:48:20Z
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?
Simply Wall St. âĸ 2026-05-14T06:13:26Z
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
Benzinga âĸ 2026-05-13T17:54:35Z
Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga âĸ 2026-05-13T13:03:54Z
Pfizer Shifts VEPPANU Rights To Rigel As Valuation Gap Persists
Simply Wall St. âĸ 2026-05-13T08:17:32Z
Arvinas Inc (ARVN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Revenue Decline
GuruFocus.com âĸ 2026-05-12T19:01:05Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $262,600,000 | $263,400,000 | $78,500,000 | $131,400,000 |
| Operating Revenue | $262,600,000 | $263,400,000 | $78,500,000 | $131,400,000 |
| Expenses | ||||
| Total Expenses | $381,100,000 | $513,600,000 | $480,000,000 | $394,600,000 |
| Other Income Expense | $-400,000 | $-2,900,000 | $-1,200,000 | $200,000 |
| Other Non Operating Income Expenses | $-400,000 | $-2,900,000 | $-1,200,000 | $200,000 |
| Net Non Operating Interest Income Expense | $38,400,000 | $54,800,000 | $38,800,000 | $12,000,000 |
| Operating Expense | $381,100,000 | $513,600,000 | $480,000,000 | $394,600,000 |
| General And Administrative Expense | $95,900,000 | $165,400,000 | $100,300,000 | $79,600,000 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-80,800,000 | $-198,900,000 | $-367,300,000 | $-282,500,000 |
| Net Interest Income | $38,400,000 | $54,800,000 | $38,800,000 | $12,000,000 |
| Interest Income | $38,400,000 | $54,800,000 | $38,800,000 | $12,000,000 |
| Normalized Income | $-80,800,000 | $-198,900,000 | $-367,300,000 | $-282,500,000 |
| Net Income From Continuing And Discontinued Operation | $-80,800,000 | $-198,900,000 | $-367,300,000 | $-282,500,000 |
| Total Operating Income As Reported | $-118,500,000 | $-250,200,000 | $-401,500,000 | $-263,200,000 |
| Net Income Common Stockholders | $-80,800,000 | $-198,900,000 | $-367,300,000 | $-282,500,000 |
| Net Income | $-80,800,000 | $-198,900,000 | $-367,300,000 | $-282,500,000 |
| Net Income Including Noncontrolling Interests | $-80,800,000 | $-198,900,000 | $-367,300,000 | $-282,500,000 |
| Net Income Continuous Operations | $-80,800,000 | $-198,900,000 | $-367,300,000 | $-282,500,000 |
| Earnings From Equity Interest Net Of Tax | $0 | $0 | $-2,500,000 | $-10,600,000 |
| Pretax Income | $-80,500,000 | $-198,300,000 | $-363,900,000 | $-251,000,000 |
| Interest Income Non Operating | $38,400,000 | $54,800,000 | $38,800,000 | $12,000,000 |
| Operating Income | $-118,500,000 | $-250,200,000 | $-401,500,000 | $-263,200,000 |
| Earnings From Equity Interest | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-1.14 | $-2.77 | $-6.62 | $-5.31 |
| Basic EPS | $-1.14 | $-2.77 | $-6.62 | $-5.31 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-113,300,000 | $-243,600,000 | $-394,800,000 | $-255,000,000 |
| Reconciled Depreciation | $5,200,000 | $6,600,000 | $6,700,000 | $8,200,000 |
| EBITDA (Bullshit earnings) | $-113,300,000 | $-243,600,000 | $-394,800,000 | $-255,000,000 |
| EBIT | $-118,500,000 | $-250,200,000 | $-401,500,000 | $-263,200,000 |
| Diluted Average Shares | $70,900,000 | $71,900,000 | $55,500,000 | $53,200,000 |
| Basic Average Shares | $70,900,000 | $71,900,000 | $55,500,000 | $53,200,000 |
| Diluted NI Availto Com Stockholders | $-80,800,000 | $-198,900,000 | $-367,300,000 | $-282,500,000 |
| Tax Provision | $300,000 | $600,000 | $900,000 | $20,900,000 |
| Research And Development | $285,200,000 | $348,200,000 | $379,700,000 | $315,000,000 |
| Selling General And Administration | $95,900,000 | $165,400,000 | $100,300,000 | $79,600,000 |
| Other Gand A | $95,900,000 | $165,400,000 | $100,300,000 | $79,600,000 |
Fetched: 2026-06-11
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $433,800,000 | $561,600,000 | $660,000,000 | $564,900,000 |
| Total Assets | $717,900,000 | $1,091,400,000 | $1,304,600,000 | $1,268,800,000 |
| Total Non Current Assets | $17,200,000 | $24,100,000 | $24,400,000 | $28,600,000 |
| Other Non Current Assets | $3,800,000 | $8,100,000 | $10,400,000 | $10,800,000 |
| Current Assets | $700,700,000 | $1,067,300,000 | $1,280,200,000 | $1,240,200,000 |
| Other Current Assets | $8,900,000 | $14,200,000 | $6,500,000 | $21,400,000 |
| Receivables | $6,400,000 | $13,700,000 | $7,200,000 | $8,000,000 |
| Other Receivables | $5,400,000 | $8,000,000 | $7,200,000 | $7,000,000 |
| Accounts Receivable | $1,000,000 | $5,700,000 | $0 | $1,000,000 |
| Cash Cash Equivalents And Short Term Investments | $685,400,000 | $1,039,400,000 | $1,261,000,000 | $1,205,300,000 |
| Cash And Cash Equivalents | $142,900,000 | $100,500,000 | $311,700,000 | $81,300,000 |
| Restricted Cash | - | $0 | $5,500,000 | $5,500,000 |
| Non Current Accounts Receivable | - | - | - | $10,800,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $8,900,000 | $9,700,000 | $3,200,000 | $5,500,000 |
| Long Term Debt And Capital Lease Obligation | $7,200,000 | $7,900,000 | $1,300,000 | $3,700,000 |
| Long Term Debt | $400,000 | $600,000 | $800,000 | $1,000,000 |
| Current Debt And Capital Lease Obligation | $1,700,000 | $1,800,000 | $1,900,000 | $1,800,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $284,100,000 | $529,800,000 | $644,600,000 | $703,900,000 |
| Total Non Current Liabilities Net Minority Interest | $141,600,000 | $300,000,000 | $387,500,000 | $408,800,000 |
| Other Non Current Liabilities | $100,000 | $100,000 | - | - |
| Non Current Deferred Liabilities | $134,300,000 | $292,000,000 | $386,200,000 | $405,100,000 |
| Current Liabilities | $142,500,000 | $229,800,000 | $257,100,000 | $295,100,000 |
| Current Deferred Liabilities | $71,300,000 | $156,200,000 | $163,000,000 | $218,600,000 |
| Payables And Accrued Expenses | $52,000,000 | $49,400,000 | $66,500,000 | $56,000,000 |
| Payables | $29,200,000 | $16,600,000 | $18,500,000 | $16,000,000 |
| Total Tax Payable | $4,800,000 | $3,200,000 | $700,000 | $10,300,000 |
| Income Tax Payable | $4,800,000 | $3,200,000 | $700,000 | $10,300,000 |
| Accounts Payable | $24,400,000 | $13,400,000 | $17,800,000 | $5,700,000 |
| Equity | ||||
| Common Stock Equity | $433,800,000 | $561,600,000 | $660,000,000 | $564,900,000 |
| Total Equity Gross Minority Interest | $433,800,000 | $561,600,000 | $660,000,000 | $564,900,000 |
| Stockholders Equity | $433,800,000 | $561,600,000 | $660,000,000 | $564,900,000 |
| Gains Losses Not Affecting Retained Earnings | $1,200,000 | $1,000,000 | $-3,100,000 | $-19,200,000 |
| Other Equity Adjustments | $1,200,000 | $1,000,000 | $-3,100,000 | $-19,200,000 |
| Retained Earnings | $-1,612,400,000 | $-1,531,600,000 | $-1,332,700,000 | $-965,400,000 |
| Other | ||||
| Treasury Shares Number | $10,000,000 | - | $0 | - |
| Ordinary Shares Number | $63,500,000 | $68,800,000 | $68,000,000 | $53,200,000 |
| Share Issued | $73,500,000 | $68,800,000 | $68,000,000 | $53,200,000 |
| Tangible Book Value | $433,800,000 | $561,600,000 | $660,000,000 | $564,900,000 |
| Invested Capital | $434,200,000 | $562,200,000 | $660,800,000 | $565,900,000 |
| Working Capital | $558,200,000 | $837,500,000 | $1,023,100,000 | $945,100,000 |
| Capital Lease Obligations | $8,500,000 | $9,100,000 | $2,400,000 | $4,500,000 |
| Total Capitalization | $434,200,000 | $562,200,000 | $660,800,000 | $565,900,000 |
| Treasury Stock | $91,900,000 | $0 | - | - |
| Additional Paid In Capital | $2,136,900,000 | $2,092,200,000 | $1,995,700,000 | $1,549,400,000 |
| Capital Stock | $0 | $0 | $100,000 | $100,000 |
| Common Stock | $0 | $0 | $100,000 | $100,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $134,300,000 | $292,000,000 | $386,200,000 | $405,100,000 |
| Long Term Capital Lease Obligation | $6,800,000 | $7,300,000 | $500,000 | $2,700,000 |
| Current Deferred Revenue | $71,300,000 | $156,200,000 | $163,000,000 | $218,600,000 |
| Current Capital Lease Obligation | $1,700,000 | $1,800,000 | $1,900,000 | $1,800,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $17,500,000 | $22,400,000 | $25,700,000 | $18,700,000 |
| Current Accrued Expenses | $22,800,000 | $32,800,000 | $48,000,000 | $40,000,000 |
| Net PPE | $13,400,000 | $16,000,000 | $14,000,000 | $17,800,000 |
| Accumulated Depreciation | $-28,200,000 | $-25,600,000 | $-21,100,000 | $-16,600,000 |
| Gross PPE | $41,600,000 | $41,600,000 | $35,100,000 | $34,400,000 |
| Leases | $9,100,000 | $9,300,000 | $11,500,000 | $10,900,000 |
| Other Properties | $29,500,000 | $29,600,000 | $21,000,000 | $21,500,000 |
| Machinery Furniture Equipment | $3,000,000 | $2,700,000 | $2,600,000 | $2,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $542,500,000 | $938,900,000 | $949,300,000 | $1,124,000,000 |
Fetched: 2026-06-11
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-275,700,000 | $-261,100,000 | $-350,700,000 | $-280,300,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-273,800,000 | $-259,300,000 | $-347,800,000 | $-273,500,000 |
| Cash Flow From Continuing Operating Activities | $-273,800,000 | $-259,300,000 | $-347,800,000 | $-273,500,000 |
| Operating Gains Losses | - | $2,600,000 | $900,000 | $400,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,900,000 | $-1,800,000 | $-2,900,000 | $-6,800,000 |
| Investing Cash Flow | $407,600,000 | $34,700,000 | $203,500,000 | $242,800,000 |
| Cash Flow From Continuing Investing Activities | $407,600,000 | $34,700,000 | $203,500,000 | $242,800,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-91,900,000 | $0 | $0 | - |
| Issuance Of Capital Stock | $0 | $0 | $387,200,000 | $0 |
| Financing Cash Flow | $-91,400,000 | $7,900,000 | $374,700,000 | $4,700,000 |
| Cash Flow From Continuing Financing Activities | $-91,400,000 | $7,900,000 | $374,700,000 | $4,700,000 |
| Net Common Stock Issuance | $-91,900,000 | $0 | $387,200,000 | $0 |
| Common Stock Issuance | $0 | $0 | $387,200,000 | $0 |
| Net Other Financing Charges | - | - | $-17,000,000 | - |
| Other | ||||
| Repayment Of Debt | $-200,000 | $-400,000 | $0 | $0 |
| End Cash Position | $142,900,000 | $100,500,000 | $317,200,000 | $86,800,000 |
| Beginning Cash Position | $100,500,000 | $317,200,000 | $86,800,000 | $112,800,000 |
| Changes In Cash | $42,400,000 | $-216,700,000 | $230,400,000 | $-26,000,000 |
| Proceeds From Stock Option Exercised | $700,000 | $8,300,000 | $4,500,000 | $4,700,000 |
| Common Stock Payments | $-91,900,000 | $0 | $0 | - |
| Net Issuance Payments Of Debt | $-200,000 | $-400,000 | $0 | $0 |
| Net Long Term Debt Issuance | $-200,000 | $-400,000 | $0 | $0 |
| Long Term Debt Payments | $-200,000 | $-400,000 | $0 | $0 |
| Net Investment Purchase And Sale | $409,500,000 | $36,400,000 | $206,400,000 | $249,600,000 |
| Sale Of Investment | $763,700,000 | $688,500,000 | $1,162,700,000 | $1,136,000,000 |
| Purchase Of Investment | $-354,200,000 | $-652,100,000 | $-956,300,000 | $-886,400,000 |
| Net PPE Purchase And Sale | $-1,900,000 | $-1,700,000 | $-2,900,000 | $-6,800,000 |
| Sale Of PPE | $0 | $100,000 | $0 | $0 |
| Purchase Of PPE | $-1,900,000 | $-1,800,000 | $-2,900,000 | $-6,800,000 |
| Change In Working Capital | $-233,700,000 | $-140,600,000 | $-44,400,000 | $-82,600,000 |
| Change In Other Working Capital | $-242,600,000 | $-101,000,000 | $-74,600,000 | $-116,800,000 |
| Change In Other Current Liabilities | $-2,000,000 | $-1,900,000 | $-2,000,000 | $-1,900,000 |
| Change In Payables And Accrued Expense | $-1,700,000 | $-21,200,000 | $17,300,000 | $20,200,000 |
| Change In Payable | $-1,700,000 | $-21,200,000 | $17,300,000 | $20,200,000 |
| Change In Account Payable | $-1,700,000 | $-21,200,000 | $17,300,000 | $20,200,000 |
| Change In Prepaid Assets | $5,300,000 | $-7,000,000 | $14,100,000 | $-1,800,000 |
| Change In Receivables | $7,300,000 | $-9,500,000 | $800,000 | $17,700,000 |
| Changes In Account Receivables | $4,700,000 | $-5,700,000 | $1,000,000 | $14,000,000 |
| Other Non Cash Items | $-8,500,000 | $-17,200,000 | $-15,300,000 | $7,500,000 |
| Stock Based Compensation | $44,000,000 | $88,200,000 | $71,600,000 | $75,500,000 |
| Depreciation Amortization Depletion | $5,200,000 | $6,600,000 | $6,700,000 | $8,200,000 |
| Depreciation And Amortization | $5,200,000 | $6,600,000 | $6,700,000 | $8,200,000 |
| Depreciation | $5,200,000 | $6,600,000 | $6,700,000 | $8,200,000 |
| Gain Loss On Sale Of PPE | $0 | $2,600,000 | $0 | $0 |
| Net Income From Continuing Operations | $-80,800,000 | $-198,900,000 | $-367,300,000 | $-282,500,000 |
| Income Tax Paid Supplemental Data | - | $2,300,000 | $11,100,000 | $11,100,000 |
| Interest Paid Supplemental Data | - | - | $0 | $0 |
| Gain Loss On Investment Securities | - | - | $900,000 | $400,000 |
| Change In Accrued Expense | - | - | - | - |
Fetched: 2026-06-11